Literature DB >> 8853934

Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

E Yukawa1.   

Abstract

The ability to measure the serum concentrations of antiepileptic drugs, and the widespread use of this procedure, has markedly improved the treatment given to patients with epilepsy during the past 3 decades. The monitoring of antiepileptic drug concentrations in serum is necessary for the optimal drug therapy of seizures, because the therapeutic and toxic effects of these drugs are better related to serum concentration than to administered dosage. Monitoring appeared to have a major impact on improving the effectiveness and safety of antiepileptic drug therapy. The age-related variability of pharmacokinetic parameters may also require the individualisation of therapy, with subsequent re-evaluation as the person grows older. Monitoring serum concentrations of antiepileptic drugs may help to optimise the dose. A drug concentration, however, can only be regarded as a guide around which to alter the dosage according to the patient's clinical condition. Serum drug concentration monitoring is particularly useful to ensure compliance and in helping to manage combinations of antiepileptic drugs that invariably interact. The addition or deletion of other antiepileptic drugs may change dosage requirements. Therefore, routine monitoring of antiepileptic drug serum concentrations would be extremely useful, especially in the paediatric population, and in patients who require associated antiepileptic medication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853934     DOI: 10.2165/00003088-199631020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  91 in total

1.  Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update.

Authors:  E Yukawa; S Higuchi; T Aoyama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1990-07       Impact factor: 1.645

Review 2.  Carbamazepine drug interactions.

Authors:  A M Baciewicz
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

3.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

4.  Pharmacokinetics of drugs used for petit mal 'absence' epilepsy.

Authors:  M J Eadie; J H Tyrer; G A Smith; L McKauge
Journal:  Clin Exp Neurol       Date:  1977

5.  Phenobarbital pharmacokinetics and bioavailability in adults.

Authors:  E Nelson; J R Powell; K Conrad; K Likes; J Byers; S Baker; D Perrier
Journal:  J Clin Pharmacol       Date:  1982 Feb-Mar       Impact factor: 3.126

6.  Influence of age and concurrent medication on steady-state valproic acid serum level-dose ratios in Japanese paediatric patients.

Authors:  E Yukawa; A Suzuki; S Higuchi; T Aoyama
Journal:  J Clin Pharm Ther       Date:  1991-08       Impact factor: 2.512

Review 7.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of carbamazepine.

Authors:  R H Levy; B M Kerr
Journal:  J Clin Psychiatry       Date:  1988-04       Impact factor: 4.384

9.  Antiepileptic drug monitoring at the epilepsy clinic: a prospective evaluation.

Authors:  J G Larkin; A L Herrick; G M McGuire; I W Percy-Robb; M J Brodie
Journal:  Epilepsia       Date:  1991 Jan-Feb       Impact factor: 5.864

10.  Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy.

Authors:  J C Cloyd; R L Kriel; J H Fischer; R J Sawchuk; R M Eggerth
Journal:  Neurology       Date:  1983-02       Impact factor: 9.910

View more
  5 in total

1.  Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.

Authors:  Jae Eun Ahn; Angela K Birnbaum; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

2.  Effect of lamotrigine on the pharmacokinetics of carbamazepine and its active metabolite in dogs.

Authors:  K M Matar; P J Nicholls; S A Bawazir; K I Al-Khamis; M I Al-Hassan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

Review 3.  Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation.

Authors:  E Perucca; O Dulac; S Shorvon; T Tomson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.

Authors:  I Mahmood; N Chamberlin
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

5.  Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.

Authors:  Ehab S EL Desoky; Eliane Fuseau; Salah EL Din Amry; Valérie Cosson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-12       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.